Last reviewed · How we verify

NCT01279135: PARCER

Tomotherapy vs Conventional Radiation for Adjuvant Pelvic RT in Ca Cervix

Completed Phase 3 Last updated 6 February 2026
What this trial tests

Phase 3 trial testing Conventional Radiation in Cancer Cervix in 300 participants. Completed in 5 May 2020.

Timeline
1 January 2011
Primary endpoint
30 December 2019
5 May 2020

Quick facts

Lead sponsorTata Memorial Hospital
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment300
Start date1 January 2011
Primary completion30 December 2019
Estimated completion5 May 2020
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Tata Memorial Hospital

Who can join

18 and older, female only, with Cancer Cervix. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study tests Tomtherapy based Image Guided Radiation against conventional radiation techniques for it's ability to reduce long term small bowel toxicity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Conventional Radiation

Trials testing the same drug.

Other recruiting trials for Cancer Cervix

Currently open trials in the same condition.

Other Tata Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01279135.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing